Tags

Type your tag names separated by a space and hit enter

Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001.
South Med J. 2003 Oct; 96(10):974-85.SM

Abstract

BACKGROUND

PROTEKT US (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin in the United States) was established in 2000 to monitor antimicrobial resistance among respiratory tract pathogens across the United States.

METHODS

During 2000 to 2001, 75 southern US centers collected 3,867 Streptococcus pneumoniae, 1,455 Streptococccus pyogenes and 1,042 Haemophilus influenzae.

RESULTS

Overall, 46.1% of S. pneumoniae isolates were nonsusceptible to penicillin, 35.8% were resistant to erythromycin, and 0.5% were resistant to fluoroquinolones. Against S. pneumoniae the most active agents were telithromycin (99.7% susceptible), linezolid (99.8%) and the fluoroquinolones (levofloxacin 99.4%, gatifloxacin 99.5%). The prevalence of erythromycin-resistant S. pyogenes isolates was 4.5%. Telithromycin, at concentration of < or = 1 mg/L, inhibited 99.9% of S. pyogenes. The prevalence of beta-lactamase positive H. influenzae was 26.2%. Telithromycin was active (MIC90 4 mg/L) against H. influenzae, irrespective of beta-lactamase production.

CONCLUSION

The prevalence of penicillin and macrolide resistance among respiratory tract pathogens from the southern United States is high. Fluoroquinolone resistance is low. Telithromycin is highly active against respiratory tract pathogens with reduced susceptibility to beta-lactams, macrolides, and fluoroquinolones.

Authors+Show Affiliations

Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233-7331, USA. waites@path.uab.eduNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14570341

Citation

Waites, Ken, and Steve Brown. "Antimicrobial Resistance Among Isolates of Respiratory Tract Infection Pathogens From the Southern United States: Data From the PROTEKT US Surveillance Program 2000/2001." Southern Medical Journal, vol. 96, no. 10, 2003, pp. 974-85.
Waites K, Brown S. Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001. South Med J. 2003;96(10):974-85.
Waites, K., & Brown, S. (2003). Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001. Southern Medical Journal, 96(10), 974-85.
Waites K, Brown S. Antimicrobial Resistance Among Isolates of Respiratory Tract Infection Pathogens From the Southern United States: Data From the PROTEKT US Surveillance Program 2000/2001. South Med J. 2003;96(10):974-85. PubMed PMID: 14570341.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001. AU - Waites,Ken, AU - Brown,Steve, PY - 2003/10/23/pubmed PY - 2003/11/5/medline PY - 2003/10/23/entrez SP - 974 EP - 85 JF - Southern medical journal JO - South Med J VL - 96 IS - 10 N2 - BACKGROUND: PROTEKT US (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin in the United States) was established in 2000 to monitor antimicrobial resistance among respiratory tract pathogens across the United States. METHODS: During 2000 to 2001, 75 southern US centers collected 3,867 Streptococcus pneumoniae, 1,455 Streptococccus pyogenes and 1,042 Haemophilus influenzae. RESULTS: Overall, 46.1% of S. pneumoniae isolates were nonsusceptible to penicillin, 35.8% were resistant to erythromycin, and 0.5% were resistant to fluoroquinolones. Against S. pneumoniae the most active agents were telithromycin (99.7% susceptible), linezolid (99.8%) and the fluoroquinolones (levofloxacin 99.4%, gatifloxacin 99.5%). The prevalence of erythromycin-resistant S. pyogenes isolates was 4.5%. Telithromycin, at concentration of < or = 1 mg/L, inhibited 99.9% of S. pyogenes. The prevalence of beta-lactamase positive H. influenzae was 26.2%. Telithromycin was active (MIC90 4 mg/L) against H. influenzae, irrespective of beta-lactamase production. CONCLUSION: The prevalence of penicillin and macrolide resistance among respiratory tract pathogens from the southern United States is high. Fluoroquinolone resistance is low. Telithromycin is highly active against respiratory tract pathogens with reduced susceptibility to beta-lactams, macrolides, and fluoroquinolones. SN - 0038-4348 UR - https://www.unboundmedicine.com/medline/citation/14570341/Antimicrobial_resistance_among_isolates_of_respiratory_tract_infection_pathogens_from_the_southern_United_States:_data_from_the_PROTEKT_US_surveillance_program_2000/2001_ DB - PRIME DP - Unbound Medicine ER -